Company Renalytix Plc

Equities

RENX

GB00BYWL4Y04

Advanced Medical Equipment & Technology

Market Closed - London S.E. 11:35:27 2024-04-25 am EDT 5-day change 1st Jan Change
25.5 GBX -3.77% Intraday chart for Renalytix Plc -15.00% +64.52%

Business Summary

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Number of employees: 102

Sales per Business

GBP in Million2022Weight2023Weight Delta
Artificial Intelligence-enabled in Vitro Diagnostics
100.0 %
2 100.0 % 3 100.0 % +26.61%

Sales per region

GBP in Million2022Weight2023Weight Delta
United Kingdom
100.0 %
2 100.0 % 3 100.0 % +26.61%

Managers

Managers TitleAgeSince
Founder 56 18-03-14
Director of Finance/CFO 54 18-03-14
President 66 19-07-28
Chief Tech/Sci/R&D Officer 57 18-03-14
Chief Tech/Sci/R&D Officer 70 18-03-14
Corporate Officer/Principal - 21-07-21
Sales & Marketing - 21-06-06
Corporate Secretary - -
Sales & Marketing 64 21-10-06
Corporate Officer/Principal 63 23-08-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 74 21-08-29
Chairman 72 18-03-14
Founder 56 18-03-14
Chief Tech/Sci/R&D Officer 57 18-03-14
Director/Board Member 56 18-10-31
Director/Board Member 58 23-06-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 154,368,191 82,586,459 ( 53.50 %) 0 53.50 %

Shareholders

NameEquities%Valuation
The Mount Sinai Hospital
14.63 %
14,619,352 14.63 % 6 M p
10,072,500 10.08 % 4 M p
Polar Capital LLP
9.517 %
9,510,339 9.517 % 4 M p
Jefferson River Capital LLC
8.539 %
8,533,280 8.539 % 4 M p
Susquehanna Investment Group LLC
7.869 %
7,863,212 7.869 % 3 M p
Pentwater Capital Management LP
4.958 %
4,954,450 4.958 % 2 M p
Heights Capital Management, Inc.
4.253 %
4,250,000 4.253 % 2 M p
NR Holdings Ltd. (United Kingdom)
4.004 %
4,001,187 4.004 % 2 M p
Harwood Capital LLP
2.769 %
2,767,206 2.769 % 1 M p
2,746,386 2.748 % 1 M p
NameEquities%Valuation
Jefferson River Capital LLC
8.539 %
4,266,640 8.539 % 4 M p
CVI Holdings LLC
2.290 %
1,144,305 2.290 % 984 102 p
Gilder, Gagnon, Howe & Co. LLC
1.760 %
879,451 1.760 % 756 328 p
Pinnacle Associates Ltd.
1.694 %
846,534 1.694 % 728 019 p
Pentwater Capital Management LP
1.401 %
700,000 1.401 % 602 000 p
Tejara Capital Ltd.
0.8013 %
400,394 0.8013 % 344 339 p
Corient Private Wealth LLC
0.6715 %
335,514 0.6715 % 288 542 p
Gofen & Glossberg LLC
0.3767 %
188,224 0.3767 % 161 873 p
Lazard Asset Management LLC
0.2734 %
136,620 0.2734 % 117 493 p
Citadel Securities GP LLC
0.2089 %
104,392 0.2089 % 89 777 p

Company contact information

Renalytix Plc

1460 Broadway

10036, New York

+646 397 3970

http://www.renalytixai.com
address Renalytix Plc(RENX)